Logo

Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors

Share this
Harbour BioMed

Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors

Shots:

  • The US FDA has cleared the IND application of the company’s HBM9027 to commence FIH study across the US based on its anti-tumor activity and favorable safety profile due to its crosslinking dependent specificity on tumors and immune modulation activity in pre-clinical studies
  • The P-I trial is designed to investigate HBM9027’s safety, tolerability, PK and anti-tumor activity in patients with advanced solid tumors
  • HBM9027, based on HBICE platform, is a PD-L1xCD40 bispecific Ab that activates CD40 relied on PD-L1 crosslinking in multiple solid tumors

Ref: Harbour BioMed | Image: Harbour BioMed 

Related Post:- Immunovant Reports Results of Batoclimab in P-II Trial for the Treatment of Graves’ Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions